Michael W. Kalb - Jan 2, 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Executive Vice President & CFO
Signature
/s/ Michael W. Kalb
Stock symbol
CPRX
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 05:00 PM
Previous filing
Nov 25, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +7.14K 7.14K Jan 2, 2025 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -2.94K -41.2% 4.2K Jan 2, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -7.14K -1.48% $0.00 476K Jan 2, 2025 Common Stock 7.14K Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3 Derivative securities vest in equal tranches, 1/5th each on January 1, 2025, 2026, 2027, 2028 and 2029.
F4 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on January 2, 2025.